Sj. Read et al., Cortical spreading depression produces increased cGMP levels in cortex andbrain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan, BRAIN RES, 891(1-2), 2001, pp. 69-77
Migraine headache is proposed to be mediated by nitric oxide (NO). Suitable
mechanisms for eliciting increases in brain NO concentration in migraineur
s have not yet been identified, although, animal models highlight cortical
spreading depression (CSD) as a potential candidate. These studies have foc
used on CSD-associated NO release at highly acute time points (min-hours) a
nd have not employed markers of NO metabolism with direct clinical applicat
ion e.g. cGMP. The current study evaluated changes in plasma cGMP concentra
tions 3 h, 24 h and 3 days post-CSD and compared these to cortical and brai
nstem cGMP concentrations at 3 days. Moreover, this study also examined the
effect of sumatriptan, a clinically effective antimigraine agent, and tona
bersat (SB-220453) a potential novel antimigraine agent, on any observed ch
anges in cGMP. Following pre-treatment with vehicle (n=3), sumatriptan (300
b kg-l i.v, n=3) or tonabersat (SB-220453 10 mg kg(-1) i.p., n=3), CSD was
evoked in anaesthetised rats by a 6-min KCI application to the parietal co
rtex. In the vehicle-treated group a median of eight depolarisations, were
observed. Sumatriptan had no effect on the number of depolarisations, where
as tonabersat significantly reduced the number of events (median=2). No dep
olarisation events were observed throughout the recording period in the sha
m group. Following KC1 application plasma cGMP concentrations were reduced
up to 24 h post-CSD, but not significantly different from sham animals at 3
days. CSD in vehicle-treated animals produced a highly significant elevati
on in cGMP concentration in the brain stem 3 days after application of KC1,
cGMP concentration increased 2.3-fold from 68+/-8 fmol/mg in sham animals
(n=3) to 158+/-28 fmol/mg in the vehicle group. This increase in brain stem
cGMP was abolished by tonabersat pre-treatment but not by sumatriptan. (C)
2001 Elsevier Science BN. All rights reserved.